Picoplatin Clinical Results Demonstrated Results in Preclinical and Clinical Studies Biochemical studies have shown that picoplatin may overcome the mechanisms of inherent or acquired resistance to cisplatin and carboplatin. Importantly, picoplatin has shown anti-tumor activity and appears to avoid the unacceptable nephrotoxicity and neurotoxicity associated with earlier platinum analogues, as demonstrated in both animal studies and Phase 1 trials. Picoplatin has been evaluated by third-party investigators in more than 750 patients and has demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer. In addition, picoplatin has shown evidence of activity in both platinum-sensitive, -resistant and -refractory disease. In Phase 2 studies, responses were seen in platinum-resistant patients with ovarian cancer, non-small cell lung cancer, small cell lung cancer and mesothelioma. Clinical studies to date also indicate that picoplatin has an acceptable safety profile and is associated with less toxicity to the kidney and peripheral nervous system than certain other currently marketed platinum chemotherapies. Evidence suggests that picoplatin can be formulated for both oral and intravenous delivery.